WHO surveillance confirms susceptibility of influenza viruses to antivirals
The vast majority of seasonal and zoonotic influenza viruses tested remained susceptible to neuraminidase inhibitors (NAIs) and the polymerase inhibitor, baloxavir marboxil.
Strengthening the EU’s Medical Supply Chains
International Co-operation and New Technologies for Better Emergency Preparedness
Emergence and spread of NA-I223V and NA-S247N double-mutant A(H1N1)pdm09 influenza viruses with reduced oseltamivir susceptibility in the Netherlands and beyond, 2023 to 2026
These findings underscore the need for ongoing genomic and phenotypic monitoring of antiviral susceptibility.
Effectiveness of Oseltamivir in Hospitalized Children With Laboratory-Confirmed Influenza, 2014-2023
Oseltamivir treatment was found to decrease both the likelihood of ICU admission and hospital length of stay among pediatric patients hospitalized with laboratory-confirmed influenza.
Emergence and spread of NA-I223V and NA-S247N double-mutant A(H1N1)pdm09 influenza viruses with reduced oseltamivir susceptibility in the Netherlands and beyond, 2023 to 2026
Rapid communication - findings underscore the need for ongoing genomic and phenotypic monitoring of antiviral susceptibility.
Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population
Comparing the Australian and New Zealand experiences in the evolving COVID-19 landscape highlights differences in policy and prescribing practice.
Call for tenders (HaDEA): Framework contracts to speed up the development of and access to next-generation therapeutics for infectious diseases
The scope of the call is expected to cover the development of innovative therapeutics to treat viral infections, acute respiratory distress syndrome (ARDS) or sepsis resulting from infections.
European Medicines Agency (EMA) 2025 Annual Report
The report summarises EMA's work in evaluating and monitoring human and veterinary medicines, including approval numbers for 2025.